Alchemab Raises £60M ($82M) In Series A Financing To Advance Novel Platform For Identifying Disease-Modifying Antibody Therapeutics
Alchemab Raises £60M ($82M) In Series A Financing To Advance Novel Platform For Identifying Disease-Modifying Antibody Therapeutics
04/15/21, 8:05 AM
Location
cambridgeMoney raised
€60
Round Type
series a
Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.
Company Info
Location
cambridge, maryland, united states
Additional Info
Alchemab has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics on the basis of patient B-cell antibody repertoires. The platform uses well-defined patient samples and a range of functional and advanced analytical techniques to evaluate convergent protective antibody responses in groups of individuals that are susceptible but resilient to specific diseases.